Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company's Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage

Stock Information for Acasti Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Acasti Pharma Inc.

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial
Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)
Acasti Announces $7.5 Million Private Placement Equity Financing
Acasti to Participate in the H.C. Wainwright Global Investment Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.